Drug intelligence / Profile preview

Fortreon

Development stage
Discontinued
Lead developer
Bayer
01

Overview

Fortreon is a defunct trademark filed by Bayer Aktiengesellschaft in November 2000, intended for a veterinary endectocide product for domestic small animals. Endectocides are antiparasitic agents effective against both endoparasites (such as nematodes) and ectoparasites (such as fleas and ticks). The trademark application was published in 2001 but subsequently abandoned in January 2002. No specific active ingredients, biological targets, or clinical trial data have been publicly associated with the name, indicating that the product likely did not proceed into advanced development or commercialization.

Brand names
Fortreon

Beyond the preview

Go deeper on Fortreon.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fortreon.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call